US equities
|
NVDA
$186.64
▲+2.78%
MU
$690.00
▲+5.12%
AMD
$449.04
▲+11.04%
SPCX
$134.27
▲+8.62%
AAPL
$342.37
▼-0.52%
SNDK
$835.06
▲+3.55%
MSFT
$530.61
▼-0.99%
TSLA
$358.22
▲+4.23%
NVDA
$186.64
▲+2.78%
MU
$690.00
▲+5.12%
AMD
$449.04
▲+11.04%
SPCX
$134.27
▲+8.62%
AAPL
$342.37
▼-0.52%
SNDK
$835.06
▲+3.55%
MSFT
$530.61
▼-0.99%
TSLA
$358.22
▲+4.23%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Incannex Healthcare Inc. - Common Stock
(NQ:
IXHL
)
2.240
-0.030 (-1.32%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incannex Healthcare Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
↗
March 11, 2024
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.
Via
Talk Markets
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
↗
March 04, 2024
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
↗
March 01, 2024
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via
Talk Markets
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
↗
February 28, 2024
Via
Benzinga
What's Going On With Incannex Stock?
↗
February 28, 2024
Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint of demonstrating a large clinical effect in the psilocybin treatment group...
Via
Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
February 28, 2024
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via
Benzinga
How I Swing Trade Via Strength With Recent Examples
↗
February 25, 2024
In this video, I explain how I avoid major losses, keep my losses small, and maximize gains. I also provide some recent trades as examples.
Via
Talk Markets
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
↗
February 18, 2024
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...
Via
Talk Markets
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
↗
February 15, 2024
Via
Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
↗
February 15, 2024
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
↗
January 30, 2024
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.
Via
Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
↗
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
Podcast: International Cannabis And Psychedelics Co. Is Working 'Hand In Hand' With FDA To Forge New Therapy Frontiers
↗
January 25, 2024
Via
Benzinga
Topics
Cannabis
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
↗
January 13, 2024
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.
Via
Talk Markets
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
↗
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
↗
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Global Mofy Metaverse Reports Follow-on Offering, Joins Lyft, Coinbase Global And Other Big Stocks Moving Lower On Friday
↗
December 29, 2023
U.S. stocks traded mixed, with the Nasdaq Composite falling around 0.3% on Friday. Shares of Global Mofy Metaverse Limited (NASDAQ: GMM) shares fell sharply during Friday’s session after the company...
Via
Benzinga
Topics
Stocks
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
↗
December 27, 2023
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...
Via
Benzinga
Psychedelic Drug Stocks Index Up In December; Down YTD
↗
December 27, 2023
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.
Via
Talk Markets
Incannex Healthcare To Open First Psychedelic-Assisted Therapy Clinic In Australia
↗
December 22, 2023
Melbourne will soon open Clarion Clinics’ first exclusively dedicated facility to provide psychedelic-assisted therapies legalized in Australia.
Via
Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
↗
December 18, 2023
Biden To Decide On Psychedelic Therapy Bill
Via
Benzinga
Psychedelic Drug Stocks Index Declined 1.6% This Week
↗
December 17, 2023
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.
Via
Talk Markets
Topics
ETFs
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
December 12, 2023
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
↗
December 11, 2023
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week
↗
December 10, 2023
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.
Via
Talk Markets
Box Reports Weak Q3 Results, Joins Yext, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
December 06, 2023
U.S. stock futures traded higher this morning, with the Dow Jones futures gaining round 0.1% on Wednesday.
Via
Benzinga
Topics
Stocks
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
↗
December 05, 2023
Defense Dept. Funds Ketamine Study For PTSD Treatment
Via
Benzinga
Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
December 05, 2023
U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday.
Via
Benzinga
Topics
Stocks
November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex
↗
December 02, 2023
The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November.
Via
Talk Markets
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?
↗
December 02, 2023
These stocks are coming off a banner month, but what about the road ahead?
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >